The findings revealed that the downregulation of AGPAT4 notably reduced the expression levels of Wnt3a, β-Catenin, MMP-9, and SNAI2 in ESCs, when compared to both BC and NC groups. The gene discussed is AGPAT4; the disease is breast cancer.